Keith Z. Hazleton

Keith Z. Hazleton

Auto-generated profile, based on publicly available information

Keith Z. Hazleton

Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, Children’s Hospital Los Angeles, Keck School of Medicine at University of Southern California, Los Angeles, California, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Current Opinion in Microbiology
Verified
Journal Article
Closed access
MKMichael Kriss
Michael Kriss
KHKeith Z Hazleton
Keith Z Hazleton
NNNichole M Nusbacher
Nichole M Nusbacher
CMCasey G Martin
Casey G Martin
CLCatherine A Lozupone
Catherine A Lozupone

1 August 2011 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MCMaria Belen Cassera
Maria Belen Cassera
YZYong Zhang
Yong Zhang
KHKeith Z. Hazleton
Keith Z. Hazleton
VSVern L. Schramm
Vern L. Schramm
Malaria is a leading cause of morbidity and mortality in the tropics. Chemotherapeutic and vector control strategies have been applied for more than a century but have not been efficient in disease eradication. Increased resistance of malaria parasites to drug treatment and of mosquito vectors to insecticides requires the development of novel chemotherapeutic agents. Malaria parasites exhibit rapid nucleic acid synthesis during their intraerythrocytic growth phase. Plasmodium purine and pyrimidine metabolic pathways are distinct from those of their human hosts. Thus, targeting purine and pyrimidine metabolic pathways provides a promising route for novel drug development. Recent developments in enzymatic transition state analysis have provided an improved route to inhibitor design targeted to specific enzymes, including those of purine and pyrimidine metabolism. Modern transition state analogue drug discovery has resulted in transition state analogues capable of binding to target enzymes with unprecedented affinity and specificity. These agents can provide specific blocks in essential pathways. The combination of tight binding with the high specificity of these logically designed inhibitors, results in low toxicity and minor side effects. These features reduce two of the major problems with the current antimalarials. Transition state analogue design is being applied to generate new lead compounds to treat malaria by targeting purine and pyrimidine pathways.

1 June 2012 in Chemistry & Biology
Verified
Journal Article
Closed access
KHKeith Z. Hazleton
Keith Z. Hazleton
MHMeng-Chiao Ho
Meng-Chiao Ho
MCMaria B. Cassera
Maria B. Cassera
KCKeith Clinch
Keith Clinch
DCDouglas R. Crump
Douglas R. Crump
VSVern L. Schramm
Vern L. Schramm

11 November 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MCMaría B. Cassera
María B. Cassera
KHKeith Z. Hazleton
Keith Z. Hazleton
EMEmilio F. Merino
Emilio F. Merino
NONicanor Obaldia
Nicanor Obaldia
MHMeng-Chiao Ho
Meng-Chiao Ho
VSVern L. Schramm
Vern L. Schramm
Plasmodium falciparum causes most of the one million annual deaths from malaria. Drug resistance is widespread and novel agents against new targets are needed to support combination-therapy approaches promoted by the World Health Organization. Plasmodium species are purine auxotrophs. Blocking purine nucleoside phosphorylase (PNP) kills cultured parasites by purine starvation. DADMe-Immucillin-G (BCX4945) is a transition state analogue of human and Plasmodium PNPs, binding with picomolar affinity. Here, we test BCX4945 in Aotus primates, an animal model for Plasmodium falciparum infections. Oral administration of BCX4945 for seven days results in parasite clearance and recrudescence in otherwise lethal infections of P. falciparum in Aotus monkeys. The molecular action of BCX4945 is demonstrated in crystal structures of human and P. falciparum PNPs. Metabolite analysis demonstrates that PNP blockade inhibits purine salvage and polyamine synthesis in the parasites. The efficacy, oral availability, chemical stability, unique mechanism of action and low toxicity of BCX4945 demonstrate potential for combination therapies with this novel antimalarial agent.

1 November 2008 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MCMaría B. Cassera
María B. Cassera
KHKeith Z. Hazleton
Keith Z. Hazleton
PRPaul M. Riegelhaupt
Paul M. Riegelhaupt
EMEmilio F. Merino
Emilio F. Merino
MLMinkui Luo
Minkui Luo
VSVern L. Schramm
Vern L. Schramm
Plasmodium falciparum is a purine auxotroph, salvaging purines from erythrocytes for synthesis of RNA and DNA. Hypoxanthine is the key precursor for purine metabolism in Plasmodium. Inhibition of hypoxanthine-forming reactions in both erythrocytes and parasites is lethal to cultured P. falciparum. We observed that high concentrations of adenosine can rescue cultured parasites from purine nucleoside phosphorylase and adenosine deaminase blockade but not when erythrocyte adenosine kinase is also inhibited. P. falciparum lacks adenosine kinase but can salvage AMP synthesized in the erythrocyte cytoplasm to provide purines when both human and Plasmodium purine nucleoside phosphorylases and adenosine deaminases are inhibited. Transport studies in Xenopus laevis oocytes expressing the P. falciparum nucleoside transporter PfNT1 established that this transporter does not transport AMP. These metabolic patterns establish the existence of a novel nucleoside monophosphate transport pathway in P. falciparum.

1 September 2013 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
KCKeith Clinch
Keith Clinch
DCDouglas R. Crump
Douglas R. Crump
GEGary B. Evans
Gary B. Evans
KHKeith Z. Hazleton
Keith Z. Hazleton
JMJennifer M. Mason
Jennifer M. Mason
PTPeter C. Tyler
Peter C. Tyler